Pfizer Pulls Celebrex's FAP Indication Quickly After Slow Trial Results
This article was originally published in The Pink Sheet Daily
Executive Summary
The European Medicines Agency issues a formal review, even though the claim had been withdrawn, in order to discourage off-label use.